{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:02:32Z","timestamp":1790082152358,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    BH3 mimetics are apoptogenic but rarely cause immunogenic cell death (ICD), limiting durable antitumor immunity. We hypothesized that an ICD-inducing immunoadjuvant could convert BH3-mimetic-triggered tolerogenic apoptosis into immunogenic priming, enhancing checkpoint immunotherapy and overcoming immune evasion in AML. We in vivo evaluated the hydroxycoumarin OT-55, combined with the Bcl-xL inhibitor A-1331852, to enhance PD-1\/Tim-3 blockade in Bcl-xL-dependent murine prophylactic and bilateral AML vaccination models. To define the clinical and immunological context, we derived a nine-gene AML ICD score (\n                    <jats:italic>ATG5, CALR, CD8A, CD8B, IFNGR1, IL1B, PDIA3, PIK3CA, TLR4<\/jats:italic>\n                    ) by screening 34 ICD-associated genes in transcriptomes of three AML patient cohorts (TARGET-AML, BEAT-AML, GSE37642), retaining genes consistently associated with favorable prognosis (HR\u2009&lt;\u20091, Cox regression). These cohorts were dichotomized by median ICD score to infer immune composition (CIBERSORTx) and profile driver mutations, and to assess blast maturation. High ICD scores were associated with an immune-activated state, increased CD8\u207a T cells, activated dendritic cells, and higher\n                    <jats:italic>HAVCR2<\/jats:italic>\n                    (Tim-3) expression, consistent with a survival advantage. Bone marrow scRNA-seq from AML and healthy donors revealed ICD-related and progenitor-to-intermediate exhausted T cells, alongside T cell depletion in myelomonocytic AML. Experimentally, we used murine C1498 myelomonocytic AML cells to evaluate OT-55 combined with A-1331852 by prophylactic whole-cell vaccination for DAMP release, dependency testing (CRT neutralization and apyrase), antigen-specific CD8\u207a responses, and synergy with anti-PD-1\/anti-Tim-3 therapy in a bilateral tumor model, while monitoring hematologic and serum parameters. OT-55 reduced C1498 viability, induced CRT exposure and ATP release, and conferred CRT\/ATP-dependent, but HMGB1-independent, vaccine protection. While A-1331852 was cytotoxic yet weakly immunogenic, its combination with OT-55 enhanced DAMP release, increased CD8\u207a effector functions, and, with PD-1\/Tim-3 blockade, achieved local and distant tumor control with low toxicity. These findings identify OT-55 as an immunogenic adjuvant converting tolerogenic BH3 mimetic-driven apoptosis into ICD, providing a proof-of-concept immunogenic treatment for myelomonocytic AML.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09000-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:25:29Z","timestamp":1782941129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OT-55 reshapes tolerogenic BH3-mimetic-induced apoptosis toward immunogenic cell death in acute myeloid leukemia, potentiating PD-1\/Tim-3 blockade"],"prefix":"10.1038","volume":"17","author":[{"given":"Yejin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ji","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-8308","authenticated-orcid":false,"given":"Sruthi Reddy","family":"Gajulapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3735-152X","authenticated-orcid":false,"given":"Ji Yeon","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Orlikova-Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-8286","authenticated-orcid":false,"given":"Artur M. S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-2662","authenticated-orcid":false,"given":"Hyuk-Jin","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-8176","authenticated-orcid":false,"given":"Claudia","family":"Cerella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0115-4725","authenticated-orcid":false,"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"9000_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"9000_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","volume":"5","author":"C Restelli","year":"2024","unstructured":"Restelli C, Ruella M, Paruzzo L, Tarella C, Pelicci PG, Colombo E. Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discov. 2024;5:234\u201348.","journal-title":"Blood Cancer Discov"},{"key":"9000_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860\u201375.","journal-title":"Nat Rev Cancer"},{"key":"9000_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04017-6","volume":"21","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi L, Kepp O, Hett E, Kroemer G, Marincola FM. Immunogenic cell death in cancer: concept and therapeutic implications. J Transl Med. 2023;21:162.","journal-title":"J Transl Med"},{"key":"9000_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.tips.2020.09.004","volume":"41","author":"C Cerella","year":"2020","unstructured":"Cerella C, Dicato M, Diederich M. BH3 mimetics in AML therapy: Death and beyond? Trends Pharmacol Sci. 2020;41:793\u2013814.","journal-title":"Trends Pharmacol Sci"},{"key":"9000_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16078","volume":"8","author":"A Inoue-Yamauchi","year":"2017","unstructured":"Inoue-Yamauchi A, Jeng PS, Kim K, Chen HC, Han S, Ganesan YT, et al. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun. 2017;8:16078.","journal-title":"Nat Commun"},{"key":"9000_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ncb3596","volume":"19","author":"E Giampazolias","year":"2017","unstructured":"Giampazolias E, Zunino B, Dhayade S, Bock F, Cloix C, Cao K, et al. Mitochondrial permeabilization engages NF-kappaB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol. 2017;19:1116\u201329.","journal-title":"Nat Cell Biol"},{"key":"9000_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","volume":"185","author":"R Pan","year":"2022","unstructured":"Pan R, Ryan J, Pan D, Wucherpfennig KW, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185:1521\u201338.e1518.","journal-title":"Cell"},{"key":"9000_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41420-025-02375-2","volume":"11","author":"K Saxena","year":"2025","unstructured":"Saxena K, Hung SH, Ryu E, Singh S, Zhang Tatarata Q, Zeng Z, et al. BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism. Cell Death Discov. 2025;11:120.","journal-title":"Cell Death Discov"},{"key":"9000_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bcp.2018.12.016","volume":"162","author":"F Radogna","year":"2019","unstructured":"Radogna F, Dicato M, Diederich M. Natural modulators of the hallmarks of immunogenic cell death. Biochem Pharmacol. 2019;162:55\u201370.","journal-title":"Biochem Pharmacol"},{"key":"9000_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.canlet.2017.12.007","volume":"416","author":"JY Lee","year":"2018","unstructured":"Lee JY, Talhi O, Jang D, Cerella C, Gaigneaux A, Kim KW, et al. Cytostatic hydroxycoumarin OT52 induces ER\/Golgi stress and STAT3 inhibition triggering non-canonical cell death and synergy with BH3 mimetics in lung cancer. Cancer Lett. 2018;416:94\u2013108.","journal-title":"Cancer Lett"},{"key":"9000_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2018.07.041","volume":"438","author":"A Mazumder","year":"2018","unstructured":"Mazumder A, Lee JY, Talhi O, Cerella C, Chateauvieux S, Gaigneaux A, et al. Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: Involvement of ER stress and DAMP release. Cancer Lett. 2018;438:197\u2013218.","journal-title":"Cancer Lett"},{"key":"9000_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660\u20139.","journal-title":"Cell Res"},{"key":"9000_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9:370\u201383.","journal-title":"Cancer Discov"},{"key":"9000_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","volume":"7","author":"P Dama","year":"2019","unstructured":"Dama P, Tang M, Fulton N, Kline J, Liu H. Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7:175.","journal-title":"J Immunother Cancer"},{"key":"9000_CR16","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1002\/cam4.5549","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, Ou J, Liu N, Wang Z, Chen J, Cai Z, et al. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia. Cancer Med-Us. 2023;12:8956\u201369.","journal-title":"Cancer Med-Us"},{"key":"9000_CR17","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501\u201310.","journal-title":"Blood"},{"key":"9000_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0146-7","volume":"6","author":"R Gu","year":"2018","unstructured":"Gu R, Yang X, Wei H. Molecular landscape and targeted therapy of acute myeloid leukemia. Biomark Res. 2018;6:32.","journal-title":"Biomark Res"},{"key":"9000_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116585","volume":"473","author":"RH Wu","year":"2023","unstructured":"Wu RH, Zhu CY, Yu PH, Ma Y, Hussain L, Naranmandura H, et al. The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions. Toxicol Appl Pharmacol. 2023;473:116585.","journal-title":"Toxicol Appl Pharmacol"},{"key":"9000_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118287","volume":"189","author":"LC da Cruz","year":"2025","unstructured":"da Cruz LC, Lee Y, Paik JY, Park J, Diederich M, Cerella C. Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients. Biomed Pharmacother. 2025;189:118287.","journal-title":"Biomed Pharmacother"},{"key":"9000_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106914","volume":"196","author":"C Cerella","year":"2023","unstructured":"Cerella C, Dicato M, Diederich M. Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting. Pharmacol Res. 2023;196:106914.","journal-title":"Pharmacol Res"},{"key":"9000_CR22","doi-asserted-by":"publisher","first-page":"e1069938","DOI":"10.1080\/2162402X.2015.1069938","volume":"5","author":"AD Garg","year":"2016","unstructured":"Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology. 2016;5:e1069938.","journal-title":"Oncoimmunology"},{"key":"9000_CR23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"9000_CR24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","volume":"24","author":"L Bunse","year":"2018","unstructured":"Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018;24:1192\u2013203.","journal-title":"Nat Med"},{"key":"9000_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571508","volume":"16","author":"E Rucker-Braun","year":"2025","unstructured":"Rucker-Braun E, Falk B, Baldauf H, Massalski C, Schafer G, Altmann H, et al. Protective effects for HLA-B*40:01 and C*03:04 in NPM1-mutated AML: result of a large HLA association study. Front Immunol. 2025;16:1571508.","journal-title":"Front Immunol"},{"key":"9000_CR26","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023;13:2032\u201349.","journal-title":"Cancer Discov"},{"key":"9000_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41375-023-02076-8","volume":"38","author":"C Cerella","year":"2024","unstructured":"Cerella C, Gajulapalli SR, Lorant A, Gerard D, Muller F, Lee Y, et al. ATP1A1\/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides. Leukemia. 2024;38:67\u201381.","journal-title":"Leukemia"},{"key":"9000_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52:825\u201341.e828.","journal-title":"Immunity"},{"key":"9000_CR29","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ccell.2023.08.013","volume":"41","author":"EM Parry","year":"2023","unstructured":"Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, et al. ZNF683 marks a CD8(+) T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023;41:1803\u201316.e1808.","journal-title":"Cancer Cell"},{"key":"9000_CR30","doi-asserted-by":"crossref","unstructured":"O\u2019Melia MJ, Rohner NA, Manspeaker MP, Francis DM, Kissick HT, Thomas SN. Quality of CD8(+) T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context. Sci Adv. 2020;6:eabd7134.","DOI":"10.1126\/sciadv.abd7134"},{"key":"9000_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42455-4","volume":"14","author":"LFK Uhl","year":"2023","unstructured":"Uhl LFK, Cai H, Oram SL, Mahale JN, MacLean AJ, Mazet JM, et al. Interferon-gamma couples CD8(+) T cell avidity and differentiation during infection. Nat Commun. 2023;14:6727.","journal-title":"Nat Commun"},{"key":"9000_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1627-9","volume":"10","author":"ZC Zhu","year":"2019","unstructured":"Zhu ZC, Liu JW, Yang C, Zhao M, Xiong ZQ. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Death Dis. 2019;10:395.","journal-title":"Cell Death Dis"},{"key":"9000_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41420-020-00348-1","volume":"6","author":"S Arulananda","year":"2020","unstructured":"Arulananda S, O\u2019Brien M, Evangelista M, Harris TJ, Steinohrt NS, Jenkins LJ, et al. BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. Cell Death Discov. 2020;6:114.","journal-title":"Cell Death Discov"},{"key":"9000_CR34","doi-asserted-by":"crossref","unstructured":"Dias-Carvalho A, Margarida-Araujo A, Reis-Mendes A, Sequeira CO, Pereira SA, Guedes de Pinho P, et al. A clinically relevant dosage of mitoxantrone disrupts the glutathione and lipid metabolic pathways of the CD-1 mice brain: a metabolomics study. Int J Mol Sci. 2023;24:13126.","DOI":"10.3390\/ijms241713126"},{"key":"9000_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113605","volume":"143","author":"H Liu","year":"2024","unstructured":"Liu H, Liu Y, Lin X, Fan J, Huang Z, Li A. Mitoxantrone attenuates lipopolysaccharide-induced acute lung injury via inhibition of NEDD8 activating enzyme. Int Immunopharmacol. 2024;143:113605.","journal-title":"Int Immunopharmacol"},{"key":"9000_CR36","doi-asserted-by":"crossref","unstructured":"Hino C, Pham B, Park D, Yang C, Nguyen MHK, Kaur S, et al. Targeting the tumor microenvironment in acute myeloid leukemia: the future of immunotherapy and natural products. Biomedicines 2022;10:1410.","DOI":"10.3390\/biomedicines10061410"},{"key":"9000_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1627161","volume":"16","author":"M Liu","year":"2025","unstructured":"Liu M, Yang M, Qi Y, Ma Y, Guo Q, Guo L, et al. Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target. Front Immunol. 2025;16:1627161.","journal-title":"Front Immunol"},{"key":"9000_CR38","doi-asserted-by":"crossref","unstructured":"Mosna F. The immunotherapy of acute myeloid leukemia: a clinical point of view. Cancers (Basel). 2024;16:2359.","DOI":"10.3390\/cancers16132359"},{"key":"9000_CR39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41375-021-01432-w","volume":"36","author":"DT Johnson","year":"2022","unstructured":"Johnson DT, Zhou J, Kroll AV, Fang RH, Yan M, Xiao C, et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2022;36:994\u20131005.","journal-title":"Leukemia"},{"key":"9000_CR40","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","volume":"67","author":"AA van de Loosdrecht","year":"2018","unstructured":"van de Loosdrecht AA, van Wetering S, Santegoets S, Singh SK, Eeltink CM, den Hartog Y, et al. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67:1505\u201318.","journal-title":"Cancer Immunol Immunother"},{"key":"9000_CR41","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3324\/haematol.2020.259457","volume":"106","author":"D Stroopinsky","year":"2021","unstructured":"Stroopinsky D, Liegel J, Bhasin M, Cheloni G, Thomas B, Bhasin S, et al. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021;106:1330\u201342.","journal-title":"Haematologica"},{"key":"9000_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195\u2013211.e110.","journal-title":"Immunity"},{"key":"9000_CR43","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T Cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175:998\u20131013.e1020.","journal-title":"Cell"},{"key":"9000_CR44","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.","journal-title":"Oncoimmunology"},{"key":"9000_CR45","doi-asserted-by":"crossref","unstructured":"Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337.","DOI":"10.1136\/jitc-2019-000337corr1"},{"key":"9000_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1721810","volume":"9","author":"T Yamazaki","year":"2020","unstructured":"Yamazaki T, Buque A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9:1721810.","journal-title":"Oncoimmunology"},{"key":"9000_CR47","doi-asserted-by":"publisher","first-page":"e2022080","DOI":"10.4084\/MJHID.2022.080","volume":"14","author":"E Pelosi","year":"2022","unstructured":"Pelosi E, Castelli G, Testa U. The growing role of the BH3 mimetic drug venetoclax in the therapy of acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2022;14:e2022080.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"9000_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025;15:139.","journal-title":"Blood Cancer J"},{"key":"9000_CR49","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"9000_CR50","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/cdd.2016.5","volume":"23","author":"AD Garg","year":"2016","unstructured":"Garg AD, Romano E, Rufo N, Agostinis P. Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ. 2016;23:938\u201351.","journal-title":"Cell Death Differ"},{"key":"9000_CR51","doi-asserted-by":"crossref","unstructured":"Garciaz S, Hospital MA, Collette Y, Vey N. Venetoclax resistance in acute myeloid leukemia. Cancers (Basel). 2024;16:1091.","DOI":"10.3390\/cancers16061091"},{"key":"9000_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.","journal-title":"BMC Cancer"},{"key":"9000_CR53","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149\u201359.","journal-title":"Lancet Oncol"},{"key":"9000_CR54","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943\u201351.","journal-title":"Cell Death Differ"},{"key":"9000_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S, et al. A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17:341\u201352.","journal-title":"Cell Stem Cell"},{"key":"9000_CR56","doi-asserted-by":"crossref","unstructured":"Dolina JS, Lee J, Brightman SE, McArdle S, Hall SM, Thota RR, et al. Linked CD4+\/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression. J Clin Invest 2023;133:e164258.","DOI":"10.1172\/JCI164258"},{"key":"9000_CR57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119","volume":"119","author":"J Chen","year":"2022","unstructured":"Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc Natl Acad Sci USA. 2022;119:e2207841119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9000_CR58","doi-asserted-by":"crossref","unstructured":"Abaza Y, Zeidan AM. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells. 2022;11:2249.","DOI":"10.3390\/cells11142249"},{"key":"9000_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303080","volume":"35","author":"DS Kuen","year":"2023","unstructured":"Kuen DS, Hong J, Lee S, Koh CH, Kwak M, Kim BS, et al. A personalized cancer vaccine that induces synergistic innate and adaptive immune responses. Adv Mater. 2023;35:e2303080.","journal-title":"Adv Mater"},{"key":"9000_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"9000_CR61","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e859.","journal-title":"Cancer Cell"},{"key":"9000_CR62","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"9000_CR63","doi-asserted-by":"crossref","unstructured":"Shrestha M, Mandal B, Mandal V, Karki S, Thapa R. Drug sensitivity patterns across FAB subtypes and molecular mutations in AML: a comprehensive analysis for precision medicine. Clin Transl Discov. 2025;5:e70046.","DOI":"10.1002\/ctd2.70046"},{"key":"9000_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0040-9","volume":"8","author":"C Saygin","year":"2018","unstructured":"Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, et al. Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J. 2018;8:4.","journal-title":"Blood Cancer J"},{"key":"9000_CR65","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1016\/j.bmc.2014.03.046","volume":"22","author":"O Talhi","year":"2014","unstructured":"Talhi O, Schnekenburger M, Panning J, Pinto DG, Fernandes JA, Almeida Paz FA, et al. Bis(4-hydroxy-2H-chromen-2-one): synthesis and effects on leukemic cell lines proliferation and NF-kappaB regulation. Bioorg Med Chem. 2014;22:3008\u201315.","journal-title":"Bioorg Med Chem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09000-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09000-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:04:03Z","timestamp":1790078643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09000-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9000"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09000-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were conducted according to the guidelines of the Institute of Animal Care and Use Committee (IACUC) at Seoul National University, Seoul, South Korea. The study protocol received approval from the IACUC Ethics Committee (SNU-191106-1-1, SNU-210305-1-1, and SNU-220510-1). All analyses used data from publicly available human AML datasets, in accordance with the guidelines of the Institutional Review Board (IRB) at Seoul National University, Seoul, South Korea (approval no E2503\/004-005).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors have read and approved the manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"821"}}